Rapid scale-up of antiretroviral treatment programmes is happening in Africa, driven by
international advocacy and policy directives and supported by unprecedented donor funding …

Objectives: To estimate stage-specific transition probabilities in individuals coinfected with
HIV and hepatitis C virus (HCV), to examine the effect of covariates on these rates, and to …

Persons at high risk for human immunodeficiency virus (HIV) infection are also likely to be at
risk for other infectious pathogens, including hepatitis B virus (HBV) or hepatitis C virus …

The article presents guidelines from the British HIV Association for the treatment of HIV-1-
infected adults using antiretroviral therapy. It presents data from clinical trials on the …

One of the toxicities linked to the use of antiretrovirals is the elevation of transaminases.
Liver toxicity is a cause of morbidity, mortality, and treatment discontinuation in HIV-infected …

The impact of human immunodeficiency virus (HIV) coinfection on the survival of patients
with hepatitis C virus (HCV)‐related end‐stage liver disease (ESLD) is unknown. Because …

Highly active antiretroviral therapy (HAART)‐related hepatotoxicity complicates the
management of patients infected with human immunodeficiency virus (HIV), increases …

Antiretroviral drug-related liver injury (ARLI) is a common cause of morbidity, mortality and
treatment discontinuation in HIV-infected patients [1]. Prevention and management of ARLI …

Due to the improved effectiveness and safety of combined antiretroviral therapy, human
immunodeficiency virus (HIV) infection has become a manageable, chronic condition rather …

Objectives: To define the incidence of fibrosis progression among hepatitis C virus
(HCV)/HIV-co-infected adults, to assess whether HCV or HIV treatment alters the risk of …